Wow, People Really Have A Handle On This Coronavirus

Yep:

The death toll from COVID-19 surpassed half a million people on Sunday, according to a Reuters tally, a grim milestone for the global pandemic that seems to be resurgent in some countries even as other regions are still grappling with the first wave. 

**

Regarding what his government would have done differently, given the opportunity to re-do the pandemic roll-out, Trudeau said that there was a number of things he wish was done differently, ...

(Sidebar: oh, really?)

... but that his government is still focused on getting Canada through a potential second wave, also noting that Canada would be prepared fiscally if that scenario were to manifest. 

(Sidebar: liar.)

**

Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at US$2,340 for a five-day treatment in the United States and some other developed countries, it said on Monday, as it set the price for a single vial at US$390.

The price for U.S. private insurance companies will be US$520 per vial, the drugmaker said, which equates to US$3,120 per patient for a treatment course using 6 vials of remdesivir.

This is below the US$5,080 per course recommendation by U.S. drug pricing research group, the Institute for Clinical and Economic Review, last week.

But everyone made sure that the liquor stores were open:

People with intellectual disabilities and autism are dying of COVID-19 at higher rates than other people in at least two states in the U.S., according to new data collected by NPR.

In Pennsylvania, people with intellectual disabilities and autism are dying at a rate twice as high as other people who contract the virus. In New York, they’re dying at 2.5 times the rate of others.

One in four Canadians — about 25 per cent of the population — has a disability, according to the latest data from Statistics Canada, and experts worry the numbers are similar when it comes to COVID-19 deaths in Canada.